Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
Overview of AngioDynamics
Founded in 1988 and headquartered in Queensbury, New York, AngioDynamics, Inc. (NASDAQ: ANGO) is a leading provider of innovative medical devices designed to enhance patient care through minimally invasive treatments. The company serves healthcare professionals, including interventional radiologists, nephrologists, and surgeons, by offering advanced solutions for treating cancer, peripheral vascular diseases, and other critical health conditions. AngioDynamics operates within the high-growth medical technology sector, focusing on improving patient outcomes and addressing complex medical challenges.
Core Business and Product Portfolio
AngioDynamics designs, manufactures, and markets a diverse range of medical devices across several key categories:
- Oncology Solutions: Technologies such as the NanoKnife® System and radiofrequency ablation devices enable precise, minimally invasive treatment of tumors, offering patients less invasive alternatives to traditional surgical procedures.
- Vascular Access and Peripheral Vascular Devices: Products include angiographic accessories, angioplasty devices, thrombolytic products, and venous solutions, which are critical for managing vascular health and ensuring effective blood flow.
- Dialysis and Drainage Products: These devices support nephrologists and other healthcare providers in managing kidney-related conditions and fluid drainage requirements.
The company’s commitment to innovation is evident in its focus on developing next-generation technologies that meet the evolving needs of healthcare providers and patients. By prioritizing research and development, AngioDynamics has built a robust portfolio that addresses both diagnostic and therapeutic applications.
Market Position and Competitive Landscape
AngioDynamics operates in a competitive and technologically advanced industry alongside major players such as Medtronic, Boston Scientific, and Abbott. The company differentiates itself through its focus on niche technologies like the NanoKnife® System, which offers a unique approach to cancer treatment by utilizing irreversible electroporation. Additionally, its emphasis on minimally invasive solutions aligns with the broader healthcare trend toward reducing recovery times and improving patient experiences.
While AngioDynamics derives a significant portion of its revenue from the U.S. market, it also seeks to expand its global footprint. Challenges include navigating regulatory environments, maintaining a steady innovation pipeline, and addressing pricing pressures in the healthcare sector.
Commitment to Patient Outcomes and Innovation
AngioDynamics is dedicated to advancing medical care by delivering technologies that improve clinical outcomes. Its minimally invasive devices not only enhance procedural efficiency but also reduce patient recovery times, making them an essential part of modern healthcare practices. The company’s forward-looking strategy involves continuous innovation to address unmet medical needs and adapt to changing industry dynamics.
Conclusion
With a strong focus on innovation, a diverse product portfolio, and a commitment to improving patient outcomes, AngioDynamics is well-positioned in the medical technology space. By addressing critical health challenges through minimally invasive solutions, the company continues to play a vital role in advancing healthcare practices worldwide.
AngioDynamics, Inc. (NASDAQ: ANGO), a leader in minimally invasive medical devices, announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the 24th Annual Needham Virtual Growth Conference on January 10, 2022, at 2:00 p.m. ET. Investors can access a live webcast through the Company’s website, with a replay available afterward. AngioDynamics specializes in products for vascular access, peripheral vascular disease, and oncology, including market-leading ablation systems and vascular access products.
AngioDynamics, Inc. (NASDAQ: ANGO) announced it will report its second quarter financial results for fiscal year 2022 on January 6, 2022, prior to market open. The management will conduct a conference call at 8:00 a.m. ET on the same day to discuss these results. Interested participants can join by calling 1-877-407-0784 domestically or +1-201-689-8560 internationally, using passcode 13725681. The call will also be accessible via webcast on AngioDynamics' website, with a replay available later that day.
AngioDynamics reported fiscal 2022 Q1 results with net sales of $77.0 million, a 9.6% increase year-over-year. Gross margin rose to 52.1%, up 120 basis points. The company reported a GAAP loss per share of $0.18 and an adjusted loss of $0.02. Notably, Med Tech sales surged 68.0% to $17.6 million, driven by the Auryon platform. U.S. sales increased 19.1%, but international sales fell 22.4%. The company raised its FY2022 sales guidance to $310-$315 million.
AngioDynamics, Inc. (NASDAQ: ANGO) will announce its first-quarter fiscal year 2022 financial results on
AngioDynamics (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the 41st Annual Canaccord Genuity Virtual Growth Conference on August 11, 2021, at 9:00 a.m. ET. A live webcast of the presentation will be available on the company’s website and can be replayed afterward. AngioDynamics specializes in minimally invasive medical devices for vascular access and oncology, offering a range of products including ablation systems and vascular access solutions.
AngioDynamics (ANGO) reported Q4 fiscal 2021 net sales of $76.8 million, up 31.7% year-over-year. Endovascular Therapies saw a 72.3% increase, driven by Auryon and AngioVac sales, while oncology sales rose 14.2%. Despite these gains, the company incurred a net loss of $19.5 million, including a $14.0 million write-off. For FY 2021, net sales reached $291.0 million, a 10.2% increase, but net loss was $31.5 million. Looking ahead, FY 2022 guidance estimates net sales of $305 to $310 million and adjusted EPS of $0.00 to $0.05, reflecting ongoing investment in product launches.
AngioDynamics (NASDAQ: ANGO) announced its upcoming virtual Investor & Technology Day on July 13, from 9:30 to 11:30 a.m. ET. The event will feature presentations from the executive leadership team, discussing the company’s growth strategy, key technology platforms, and financial goals. Interested parties can register via the company’s website. A live webcast and archive of the presentation will also be available on the Investors section of the AngioDynamics website.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for Q4 and fiscal year 2021 on July 13, 2021, before market open. A conference call is scheduled for 8:00 a.m. ET for management to discuss these results. Investors can dial in using a specified number or access through a webcast on the company's website. Additionally, AngioDynamics will host a virtual Investor & Technology Day on the same day at 9:30 a.m. ET. Details and registration information will be provided on their website.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that it received 510(k) clearance from the FDA for the AlphaVac Mechanical Thrombectomy System, designed for non-surgical removal of thrombi or emboli. The commercial release is anticipated in the second half of 2021. Additionally, the Company will report its fourth quarter and fiscal year 2021 financial results on July 13, 2021, with a conference call scheduled at 8:00 a.m. ET, followed by a virtual Investor and Technology Day at 9:30 a.m. ET.
AngioDynamics, Inc. (NASDAQ: ANGO), a top provider of minimally invasive medical devices, announced Jim Clemmer, President and CEO, will present at the UBS Virtual Global Healthcare Conference on May 25, 2021, at 12:00 p.m. ET. The live webcast can be accessed through the company’s website and will be available for replay afterward.
The company specializes in devices for vascular access, peripheral vascular disease, and oncology, with a product range that includes ablation systems and drainage products. For further details, visit www.angiodynamics.com.
FAQ
What is the current stock price of Angiodynamics (ANGO)?
What is the market cap of Angiodynamics (ANGO)?
What does AngioDynamics specialize in?
What is the NanoKnife® System?
Who are AngioDynamics' primary customers?
How does AngioDynamics differentiate itself from competitors?
What challenges does AngioDynamics face in its industry?
What is AngioDynamics' approach to innovation?
Where does AngioDynamics generate most of its revenue?
What role does AngioDynamics play in the healthcare industry?
